Adenosine Therapeutics

Board of Directors

Robert S. Capon, MBA, Chairman, CEO, and Co-founder
See bio under management team.
H. Jeff Leighton, Ph.D.
H. Jefferson Leighton received a Ph.D. in Pharmacology from the University of Virginia. He has over 20 years of multi-national experience in the pharmaceutical industry, including11 years at Burroughs Wellcome, where he was a Principle Scientist for the Corporation, and 6 years at Glaxo, where he was a V.P. for Research and Group Director for Cardiovascular and Metabolic Diseases. After his tenure in big pharma, Jeff became a biotech entrepreneur, founding Inspire Pharmaceuticals, ICAgen, AdipoGenix, BioDesign and, most recently, RxDesign Pharmaceuticals. Jeff also serves on various biopharmaceutical boards and has made key inventions leading to development products for Hypnion (sleep medicines), Artesian (congestive heart failure), and Descartes (pain modulation).

Recently, Dr. Leighton founded Exodos & Associated Companies, and Milestone Pharma. Presently he operates a natural products and nutrition science based company called Stronger Faster Healthier. In addition, Dr. Leighton was a co-inventor of remifentanil (Ultiva), has conceptualized and developed to an NDA filing five other new chemical entities, and holds many other patents. Jeff classifies his activities as those of a seasoned Drug Hunter. He lives and works in Boston.
Joel M. Linden, Ph.D., Senior Science Advisor & Co-founder
Joel M. Linden, is the Co-Founder of Adenosine Therapeutics. He is a Professor in the Division of Inflammation Biology at the La Jolla Institute of Allergy & Immunology and a leading expert on adenosine receptors, which are important for regulating inflammation.

Dr. Linden received a B.S. from Brown University in Applied Mathematics and Biology and a Ph.D. from the University of Virginia in Pharmacology.

Dr. Linden has devoted the past 25 years to the study of the pharmacology, physiology and molecular biology of adenosine receptors and has co-authored over 120 papers and 15 book chapters on this subject. Dr. Linden is the former Chairman of the Research Committee of the Mid-Atlantic Affiliate of the American Heart Association, has served as a member of numerous NIH study sections, received the inventor of the year award from the University of Virginia, and started a successful biopharmaceutical company, Adenosine Therapeutics.
Timothy L. Macdonald, Ph.D.
Professor Timothy Macdonald is a former Chair of the Department of Chemistry at the University of Virginia. He has delivered over 100 invited lectures at universities and scientific conferences, has written over 130 publications, and has made contributions to over a dozen patents. The research program on which Professor Macdonald focuses works to elucidate biological mechanisms and to develop approaches for modulating these processes. During the past 10 years, Professor Macdonald's research program has investigated several pathways associated with cellular proliferation, cellular defenses and idiosyncratic drug reactions and has developed a number of agents that target these processes.

Awards received by Professor Macdonald: the Alfred P. Sloan Award, the Eli Lilly Young Investigator Award, the Cyanamid Award for Excellence in the Advancement of Chemical Synthesis, and, for the work on AlGlutamine, the Henderson Inventor of the Year Award at the University of Virginia (jointly with Dr. Richard Guerrant).

Professor Macdonald received a B. S. degree from the University of California, Los Angeles in 1971, a Ph.D. degree in chemistry from Columbia University in 1975, and undertook postdoctoral studies at Stanford University
Henry Skinner, Ph.D.
Dr. Skinner is the representative on the board of Novartis Bioventures, Ltd. Prior to the Novartis Venture Funds he worked as Executive Director and Global Head Strategic Alliances, Therapeutics and Head Strategic Alliances, Technologies at the Novartis Institutes for Biomedical Research where he led a team responsible for identification, negotiation and management of collaborations and licenses for Novartis? therapeutic areas as well as the technology areas.

Prior to joining Novartis he was CEO of SelectX Pharmaceuticals and President and CEO of NeoGenesis Pharmaceuticals, which was acquired by Schering-Plough. He was also Director of Technology Acquisitions for Pharmacia & Upjohn and Pharmacia managing business development and licensing for Pharmacia?s research platforms and therapeutic areas worldwide, and Director of Business Development at Lexicon Genetics. He was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics and earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois. Henry serves on the board of AMP Therapeutics, Galera Therapeutics and works with Cylene, Merus and Forma.



Home | Corporate | Partnering | Contacts
2013 Adenosine Therapeutics, LLC. All rights reserved.